| Display title | Chemistry:Pegfilgrastim |
| Default sort key | Pegfilgrastim |
| Page length (in bytes) | 30,579 |
| Namespace ID | 3022 |
| Namespace | Chemistry |
| Page ID | 247373 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | imported>LinXED |
| Date of page creation | 08:46, 8 February 2024 |
| Latest editor | imported>LinXED |
| Date of latest edit | 08:46, 8 February 2024 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | Pegfilgrastim, sold under the brand name Neulasta among others, is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (GCSF) analog filgrastim. It serves to stimulate the production of white blood cells (neutrophils). Pegfilgrastim was developed by Amgen.
Pegfilgrastim treatment... |
